BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) and Renalytix (NASDAQ:RNLX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.
Valuation and Earnings
This table compares BioNexus Gene Lab and Renalytix’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioNexus Gene Lab | $9.77 million | 1.09 | -$360,000.00 | ($0.02) | -29.99 |
| Renalytix | $3.40 million | 11.79 | -$45.61 million | ($0.45) | -1.78 |
BioNexus Gene Lab has higher revenue and earnings than Renalytix. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioNexus Gene Lab | 0 | 0 | 0 | 0 | N/A |
| Renalytix | 0 | 0 | 1 | 0 | 3.00 |
Renalytix has a consensus price target of $5.00, suggesting a potential upside of 523.44%. Given Renalytix’s higher probable upside, analysts clearly believe Renalytix is more favorable than BioNexus Gene Lab.
Insider & Institutional Ownership
18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 9.9% of Renalytix shares are owned by institutional investors. 6.8% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 18.3% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares BioNexus Gene Lab and Renalytix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioNexus Gene Lab | -29.92% | -42.85% | -34.09% |
| Renalytix | -1,736.47% | -1,008.88% | -155.62% |
Summary
BioNexus Gene Lab beats Renalytix on 7 of the 11 factors compared between the two stocks.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
